• 1
    Chan JM, Jou RM, Carroll PR. The relative impact and future burden of prostate cancer in the United States. J Urol 2004; 172: 1316
  • 2
    Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 17081717
  • 3
    Zelefsky MJ, Reuter VE, Fuks Z et al. Influence of local tumour control on distal metastases after external beam radiotherapy for prostate cancer. J Urol 2008; 179: 13681373
  • 4
    Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 2002; 168: 10081012
  • 5
    Lilleby W, Fossa S, Wahre H, Olsen D. Long-term morbidity and quality of life in patients with localised prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999; 43: 735743
  • 6
    Halabi S, Vogelzang NJ, Ou S-S, Small EJ. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 cancer and leukemia group B trials. J Urol 2007; 177: 531534
  • 7
    Cheng CWS, Bergstralh EJ, Zincke H. Stage D1 prostate cancer: a nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer Suppl 1993; 71: 9961004
  • 8
    Schmeller N, Lubos W. Early endocrine therapy verus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer. Br J Urol 1997; 79: 226234
  • 9
    Gjertson C, Asher K, Sclar J et al. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology 2007; 70: 723727
  • 10
    Grimm M-O, Kamphausen H, Hugenschmidt H, Stephen-Odenthal M, Ackermann R, Vogeli TA. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol 2012; 41: 628634
  • 11
    Steinberg GD, Epstein JI, Piantadosi S, Walsh PC. Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol 1990; 144: 14251432
  • 12
    Widmark A, Klepp O, Solberg A et al. Endocrine treatment, with or without radiotherpy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301308
  • 13
    Warde P, Ding K, Kirkbride P et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 17: 21042111
  • 14
    Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242245